<DOC>
	<DOC>NCT00227435</DOC>
	<brief_summary>This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.</brief_summary>
	<brief_title>Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Documented clinical history of chronic hepatitis C and compensated liver disease No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit Other protocoldefined inclusion criteria may apply. Patient is pregnant or breastfeeding Patient is coinfected with HBV or HIV Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>